US Patent 8,047,202: Scope, Claim Analysis, Expiration, and Nasal Delivery Patent Landscape

US Patent No. 8,047,202 protects a breath-actuated nasal delivery platform in which a disposable patient-contacting interface is separated from a reusable actuator. The core combination includes one or two nasal nozzles, a mouthpiece, a substance supply unit, and an actuator triggered by exhalation. The patent is directed to device architecture, not a specific drug, formulation, or therapeutic indication.

The principal commercial relevance is to exhalation delivery systems such as Optinose-style nasal devices, including platforms used for intranasal corticosteroid delivery. The patent’s original 20-year term was tied to a February 2004 priority date, placing ordinary expiration in 2025, subject to any applicable patent-term adjustment or terminal disclaimer shown in the USPTO record. The patent does not independently create a current Orange Book exclusivity period for a drug product.

What does US Patent 8,047,202 protect?

The patent protects a nasal delivery device with four core elements:

A disposable interface unit.
One or more nosepieces with substance-delivery nozzles.
A mouthpiece through which the patient exhales.
A reusable actuation unit that responds to exhalation and actuates substance delivery.

Claim 1 is the broadest independent claim for a device with at least one nosepiece. Claim 4 is a second independent claim directed specifically to first and second nosepiece units and corresponding delivery units.

The inventive center is the separation between the disposable interface and the actuation unit. A product can fall within the claim even if the disposable unit does not contain the electronics, motor, sensor, or control circuitry, provided that the reusable actuator operates the disposable interface in response to patient exhalation.

The patent is therefore best characterized as a platform or device-architecture patent rather than a drug patent.

What are the independent claims in US 8,047,202?

Claim	Independent?	Principal technical scope
1	Yes	Disposable interface, at least one nosepiece, mouthpiece, substance supply unit, and separate exhalation-responsive actuator
4	Yes	Disposable interface with first and second nosepieces and corresponding first and second delivery units
2-3	No	Single integral interface and protective packaging
5-12	No	Pump structure, airflow, gas pre-flow, sensors, sequential delivery, and belt-fed interfaces
13-20	No	Dependent limitations directed to the bilateral configuration in claim 4

Claims 1 and 4 create two infringement routes. A device may be challenged under claim 1 using a single-nostril or one-delivery-unit configuration. Claim 4 requires bilateral architecture with two delivery units.

How broad is claim 1?

Claim 1 covers a nasal delivery device having:

A disposable interface unit;
At least one nosepiece fitted to a nostril;
A nozzle that delivers a substance;
A mouthpiece into which the patient exhales;
At least one substance supply unit;
A separate actuation unit; and
Actuation of the delivery unit in response to exhalation.

Several features materially limit the claim.

Disposable interface limitation

The interface must be disposable separately from the actuation unit. This limitation excludes a fully disposable device in which the actuator and patient-contacting interface are permanently integrated and discarded together, unless the product architecture still provides separately disposable components.

The language does not expressly require that the interface be used only once. “Disposable” generally supports a construction involving intended discard or replacement, but the exact interpretation would depend on the intrinsic record and prosecution history.

Exhalation-responsive actuation

The actuator must respond to exhalation. A conventional nasal spray actuated manually by finger pressure would not satisfy this limitation unless exhalation is part of the claimed actuation sequence.

The claim does not require a particular sensor. Exhalation may be detected through pressure, flow, a mechanical trigger, or another mechanism, subject to the limitations of dependent claims 9 and 10.

Substance supply unit

Claim 1 does not restrict the substance to a particular pharmaceutical ingredient. The term can encompass liquid, powder, suspension, solution, or other deliverable material, although claim 5 expressly identifies liquid or powder embodiments.

How does claim 4 differ from claim 1?

Claim 4 is narrower in one respect and potentially stronger in another. It requires:

First and second nosepiece units;
First and second delivery units;
A substance supply unit associated with each nosepiece; and
A common actuation unit that responds to exhalation.

A bilateral product with two independently actuated nasal delivery paths is the clearest target. Claim 4 does not expressly require a mouthpiece in the independent claim, although claim 14 adds that limitation. The claim also does not expressly require sequential delivery; that limitation appears in claim 13.

A device using one common substance reservoir to feed both nostrils could raise claim-construction issues. Claim 4 requires first and second delivery units, but it does not necessarily require two separate reservoirs if the product has two delivery mechanisms supplied from a common source.

What do claims 2 through 20 add?

Integral and packaged interface units

Claims 2, 3, 19, and 20 add commercial configuration details:

Claims 2 and 19 require the interface unit to be a single integral unit.
Claims 3 and 20 require protective packaging.

These limitations may be useful against commercial products sold as preassembled sterile or hygienically packaged patient interfaces. They are less important for proving infringement when claim 1 or claim 4 can be established without them.

Pump and piston limitations

Claim 5 requires a substance pump with:

A chamber containing substance; and
A piston movable in the chamber to deliver the substance.

Claims 7 and 15 apply similar piston-and-cylinder requirements to a gas pump. These claims narrow the patent to mechanically displaced delivery systems and do not cover every pump architecture.

A product using a diaphragm pump, piezoelectric pump, pressurized canister, or purely passive airflow system may avoid these specific dependent claims while remaining exposed under claim 1 or claim 4.

Mouthpiece airflow

Claims 6 and 14 require the mouthpiece to be fluidly connected to a nosepiece so that exhalation produces airflow through the nasal delivery path. This is an important distinction from systems in which the mouthpiece merely provides a trigger signal to electronics without forming part of the airflow path.

Gas pre-flow

Claims 7, 8, 15, and 16 require the gas supply unit to begin supplying gas before the substance supply unit is actuated. This sequencing can improve nasal delivery by establishing airflow before drug release.

The limitation is technically meaningful. A device that releases drug and airflow simultaneously may avoid these claims, even if it remains within a broader independent claim.

Pressure and flow detection

Claims 9, 10, 17, and 18 cover exhalation detection based on:

A predetermined pressure in the mouthpiece;
A predetermined flow rate through the mouthpiece;
A pressure sensor;
A flow sensor; or
A mechanical or electronic trigger mechanism.

The dependent claims are written in alternatives. A product generally need not use both pressure and flow detection to satisfy the claim. Use of either qualifying mechanism may be sufficient.

Sequential bilateral delivery

Claims 11 and 13 cover delivery first into one nasal cavity and subsequently into the other. The claims target timing and sequencing rather than merely bilateral capability.

A bilateral device that delivers simultaneously may avoid the sequential limitation, although it may still implicate claim 4 if the other elements are present.

Belt-fed interface units

Claim 12 covers multiple disposable interface units attached to a belt and sequentially presented to the reusable actuator. This is a specialized commercial-use embodiment and may be relevant to clinic, hospital, or high-throughput administration systems rather than ordinary home-use nasal sprays.

What patent claims cover formulation and drug composition?

US 8,047,202 does not claim:

Fluticasone propionate;
A specific corticosteroid;
A particular therapeutic indication;
A defined particle-size distribution;
A specific excipient system;
A pharmaceutical composition independent of the device; or
A method of treating a named disease.

Its substance-related coverage is functional. The substance must be delivered through the claimed nasal apparatus, but the patent does not create broad composition claims covering the drug itself.

Formulation and drug-product protection would ordinarily arise from separate patents covering particle engineering, suspension stability, dose uniformity, excipients, formulations, or methods of treating conditions such as chronic rhinosinusitis or nasal polyps.

What is the patent expiration date?

The patent claims priority to a February 2004 filing date, making the standard 20-year term run to approximately February 2025 under 35 U.S.C. §154. The precise enforceability date depends on the USPTO’s recorded patent-term adjustment, terminal disclaimer status, and the relevant priority chain.

Event	Approximate date or status
Earliest priority	February 2004
US application filing	2005
US patent grant	2011
Ordinary 20-year term endpoint	February 2025
Current commercial significance	Primarily historical, freedom-to-operate, and family-landscape relevance

A patent that has reached its term cannot support a new infringement action for post-expiration activity. Expiration does not eliminate its importance in invalidity analysis, prior-art assessment, or evaluation of continuation patents with later expiration dates.

Is US 8,047,202 listed in the Orange Book?

US 8,047,202 is a device patent. Orange Book listing is tied to patents that claim an approved drug substance, drug product, or approved method of use under the FDA’s patent-listing framework. A device patent is not automatically Orange Book eligible merely because the device administers an FDA-approved drug.

For products such as exhalation-delivery nasal corticosteroids, the relevant Orange Book estate may include separate patents covering:

The drug product;
The formulation;
The nasal delivery method;
The approved indication;
Dose regimen;
Device-drug combinations; or
Use of the delivery system with the approved product.

The FDA Orange Book must be reviewed for the particular NDA and product strength. US 8,047,202 should not be treated as an Orange Book-listed drug patent without a product-specific listing record. The FDA’s Orange Book framework and patent-listing requirements are separate from the existence of the device patent itself (FDA, 2024).

Does the patent create Paragraph IV risk?

The patent alone does not create a conventional Paragraph IV risk unless it was listed for a specific approved drug product and remains unexpired.

Paragraph IV exposure would arise where:

A generic applicant files an ANDA for a drug product;
The NDA holder has listed an applicable patent;
The applicant certifies that the patent is invalid, unenforceable, or not infringed; and
The patent has not expired or been disclaimed.

Because US 8,047,202 is principally a device-architecture patent and reached its ordinary term in 2025, it is unlikely to be the principal current barrier to a conventional generic nasal spray. It could still have been relevant historically to an ANDA or 505(b)(2) product using the protected delivery architecture.

A 505(b)(2) applicant using an exhalation-triggered disposable-interface platform would face a more direct device-patent analysis than a conventional generic nasal spray using a manually actuated pump.

Are biosimilars relevant to this patent?

No. Biosimilar pathways address biological products under the Public Health Service Act. US 8,047,202 claims a mechanical nasal delivery device and does not claim a biologic, biosimilar, antibody, protein sequence, or biologic manufacturing process.

The relevant competitive threats are:

Conventional generic nasal sprays;
505(b)(2) nasal products;
Alternative exhalation delivery systems;
Device substitutes; and
New drug-device combinations.

Which companies and products are most commercially relevant?

The strongest commercial association is with Optinose and its exhalation delivery system platform. Optinose’s XHANCE product uses an exhalation delivery system to deliver fluticasone propionate to the nasal passages. The commercial product includes a drug formulation and delivery device, but the product’s patent protection is distributed across multiple patent families rather than resting on US 8,047,202 alone.

Platform category	Representative commercial approach	Exposure to US 8,047,202
Conventional nasal spray	Manual pump, single nostril or bilateral spray	Generally low if no exhalation-triggered separate actuator
Exhalation delivery system	Patient exhales through mouthpiece while drug is delivered nasally	High historical relevance
Breath-powered powder device	Patient-generated airflow delivers powder	Depends on disposable interface and actuation architecture
Pressurized nasal system	Canister-driven delivery	Potentially relevant if exhalation actuates a separate disposable interface
Fully disposable electronic device	Actuator discarded with interface	May avoid the “disposable separately” limitation
Reusable actuator with replaceable cartridge	Closest structural analogue	Highest claim-mapping risk

Other nasal delivery companies may practice adjacent concepts without infringing the patent if they use different airflow pathways, manually actuated pumps, integrated disposable assemblies, or nonresponsive delivery mechanisms.

What is the patent strength?

The patent has moderate historical strength as a platform patent but limited current blocking power after ordinary expiration.

Strengths

Claims the interface-actuator separation directly.
Covers one-nostril and two-nostril configurations.
Uses functional exhalation-response language broad enough to cover sensor and trigger implementations.
Reaches device architecture rather than a single drug.
Includes fallback claims for pressure sensing, flow sensing, sequential delivery, gas pre-flow, and piston pumps.

Weaknesses

The core concepts depend on a combination of known device elements.
Prior art involving breath-actuated inhalers, nasal atomizers, disposable cartridges, and pressure-triggered delivery could support obviousness arguments under 35 U.S.C. §103.
“Disposable separately” may generate claim-construction disputes.
The patent does not protect the drug, formulation, indication, or dose.
Dependent claims are vulnerable where a competing product uses a different pump, sensor, or sequencing arrangement.
The ordinary patent term has ended or reached its endpoint based on the 2004 priority date.

What litigation and settlement issues matter?

A product-specific litigation search should distinguish among:

Patent infringement suits involving the device;
ANDA litigation over drug-product patents;
505(b)(2) litigation involving device-drug combinations;
Inter partes review or post-grant validity challenges;
License agreements for the exhalation delivery platform; and
Settlement agreements setting generic launch dates.

US 8,047,202 should not be conflated with later continuation or divisional patents. A settlement involving a later patent family may impose commercial restrictions after this patent’s expiration, but it would not extend the term of US 8,047,202 itself.

The principal legal risk now lies in later-expiring continuation patents, formulation patents, and method-of-use patents that claim the commercial product more specifically. The relevant statutory framework includes infringement under 35 U.S.C. §271, patent-term rules under §154, and patentability standards under §§102 and 103.

What geographic coverage does the patent provide?

US 8,047,202 covers conduct within the United States, including making, using, selling, offering to sell, or importing the claimed device under 35 U.S.C. §271.

It does not directly cover:

A device made and used entirely outside the United States;
Foreign sales with no US importation;
Foreign manufacturing disconnected from US activity; or
A foreign product unless a corresponding foreign patent is in force.

The international landscape must be reviewed through the patent family, including corresponding PCT, European, Canadian, Australian, and other national-stage filings. Foreign claims may differ materially from the US claims after examination.

What generic launch scenarios exist?

Scenario	Likely impact of US 8,047,202
Conventional generic nasal spray	Low direct impact
Generic using the same exhalation device	Historically significant; current impact depends on later patents
505(b)(2) product with redesigned actuator	Device claim design-around is possible
Product using a fully disposable unit	Potential avoidance of separate-disposal limitation
Product with simultaneous rather than sequential delivery	May avoid sequential dependent claims
Product using diaphragm or piezoelectric pump	May avoid piston-pump claims
Product using manual actuation	May avoid exhalation-response limitations

Key Takeaways

US 8,047,202 is a nasal-device patent, not a drug-composition patent.
Claims 1 and 4 are the principal independent claims.
The central limitation is a disposable nasal interface used with a separately reusable actuator.
Exhalation-triggered delivery is required in the independent claims.
Claim 4 specifically targets bilateral delivery with first and second delivery units.
Claims 5-20 add piston pumps, gas pre-flow, pressure or flow detection, sequential delivery, packaging, and belt-fed interfaces.
The patent does not independently protect fluticasone propionate or another specific drug.
It is not automatically an Orange Book patent.
Biosimilar competition is irrelevant; generic and 505(b)(2) competition are the relevant pathways.
The ordinary patent term traces to a February 2004 priority date and reached its endpoint in 2025, subject to the USPTO term record.
Current freedom-to-operate analysis should focus on later continuation patents, formulation patents, method-of-use patents, and product-specific Orange Book listings.

FAQs

Does US 8,047,202 cover a standard nasal spray?

Generally no. A standard manually actuated nasal spray ordinarily lacks the claimed exhalation-responsive actuator and separately disposable interface architecture.

Can a competitor avoid the patent by making the entire device disposable?

Potentially. A fully integrated disposable product may avoid the limitation requiring the interface to be disposable separately from the actuation unit, although other patent claims could apply.

Does the patent cover both liquid and powder nasal delivery?

Yes, claim 5 expressly identifies liquid or powder substances, but only in a piston-based substance pump configuration.

Does simultaneous bilateral delivery infringe claim 13?

Not necessarily. Claim 13 requires sequential delivery into one nasal cavity and then the other. Simultaneous delivery may avoid that dependent claim, while remaining potentially relevant to claim 4.

Is a later Optinose patent automatically covered by the expiration of US 8,047,202?

No. Continuation, divisional, or related patents may have different claims and later expiration dates. Each patent must be analyzed independently.

References

Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
United States Patent and Trademark Office. (2011). U.S. Patent No. 8,047,202, Nasal delivery device.
United States Code. (2024). 35 U.S.C. §§ 102, 103, 154, 271.
Food and Drug Administration. (2024). Approved drug products and patent listing requirements. U.S. Department of Health and Human Services.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0215270.0	Jul 2, 2002

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003251088	⤷ Start Trial
United Kingdom	0215270	⤷ Start Trial
United Kingdom	0315499	⤷ Start Trial
United Kingdom	2390813	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2004004814	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,047,202